KB-1777

JNJ78278343-KLK2-hIgG1

61522

Home » Antibodies » JNJ78278343-KLK2-hIgG1

Background of JNJ78278343-KLK2-hIgG1

Human kallikrein 2 (encoded by the KLK2 gene and hereafter referred to as KLK2) is a trypsin-like serine protease produced by prostate epithelial cells that has high homology and coexpression with the prostate-specific antigen (PSA)/KLK3 gene. KLK2 is regulated by androgen receptor signaling and has minimal expression in normal, nonprostate tissues,10 making it an ideal target for PC therapy. Its expression in prostate adenocarcinoma is nearly ubiquitous in the localized and castrate-sensitive settings, and high expression levels are maintained in metastatic castration-resistant PC (mCRPC). Pasritamig is a human immunoglobulin G1 bispecific antibody that simultaneously binds to CD3 receptor complexes on T cells and cell surface KLK2 on tumor cells, directing T-cell cytotoxicity to KLK2-expressing tumor cells.

Specifications

Catalog Number	KB-1777
Antibody Name	JNJ78278343-KLK2-hIgG1
Isotype	Human IgG1,kappa
FC Muations	Wild Type
Target	KLK2
Species Reactivity	Human
Host Cell Line	EXPI CHO
Purification Method	Affinity purified
Concentration	>2 mg/mL
Formulation	50 mM sodium citrate,150mM NaCl,pH5.5
Purity	>95% by SDS-PAGE and SEC-HPLC
Validation	ELISA
Endotoxin Level	<0.2 EU/mg as determined by the LAL method
Sterility	0.2μm filtered
Storage	It is recommended that the protein should be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
Stability	Stable for twelve months from date of receipt when stored at -20°C to -80°C; Stored at 2-8°C for one month without detectable loss of activity.

Characterization

Application

References

Stein MN, Vinceneux A, Robbrecht D, Doger B, Autio KA, Schweizer MT, Calvo E, Medina L, Van Dongen M, Deville JL, Bernard-Tessier A, Ghosh D, Shotts K, Shen F, Jaiprasart P, Chaudhary R, Wu S, Cartee L, Schnepp R, Gaut D, Lauring J, Wang SC, Villalobos VM, Baldini C. Pasritamig, a First-in-Class, Bispecific T-Cell Engager Targeting Human Kallikrein 2, in Metastatic Castration-Resistant Prostate Cancer: A Phase I Study. J Clin Oncol. 2025 Aug;43(22):2515-2526.